Group 1 - The company, West Point Pharmaceutical, announced a plan to repurchase its issued A-shares using self-owned and/or self-raised funds through centralized bidding [2] - The total amount for the repurchase is set to be no less than RMB 25 million and no more than RMB 50 million [2] - The repurchase price will not exceed RMB 42.00 per share [2] - The implementation period for the repurchase is within 12 months from the date the board of directors approves the plan [2]

Major Announcements - Zhaoyi Innovation plans to use 500 million CNY of A-share fundraising to increase capital in its wholly-owned subsidiaries for the implementation of the DRAM project [1] - Haiguang Information's mid-2025 profit distribution plan includes a cash dividend of 0.09 CNY per share, totaling 209 million CNY [2] - *ST Biology has terminated the major asset restructuring plan to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [3] - Fosun Pharma intends to spin off its subsidiary Fosun Antigen for independent listing on the Hong Kong Stock Exchange [4] - Jingchen Co. has set the inquiry transfer price at 82.85 CNY per share for the transfer of 13.1 million shares [5] Performance Forecasts - Zhaoyi Innovation expects a net profit of approximately 1.61 billion CNY for 2025, a year-on-year increase of about 46% [9] - Longying Precision anticipates a net profit decrease of 17.70% to 29.36% for 2025, estimating between 545 million CNY and 635 million CNY [9] - Ruichuang Micro-Nano forecasts a net profit of around 1.1 billion CNY for 2025, representing a 93% increase [10] - Nanjing Bank projects a net profit of 21.81 billion CNY for 2025, an 8.08% increase year-on-year [11] - Zhongyuan Co. expects a net profit increase of 80% to 105% for 2025, estimating between 139 million CNY and 158 million CNY [12] - Qiangyi Co. anticipates a net profit increase of 57.87% to 71.17% for 2025, estimating between 368 million CNY and 399 million CNY [13] - Liard expects a net profit of 300 million CNY to 380 million CNY for 2025, turning from a loss of 889 million CNY in the previous year [14] - Daheng Technology forecasts a net profit of approximately 106 million CNY for 2025, also turning from a loss [16] - Dongfeng Co. anticipates a net loss of 390 million CNY to 480 million CNY for 2025 [17] - Qing Song Co. expects a net profit increase of 137.73% to 201.74% for 2025, estimating between 130 million CNY and 165 million CNY [18] - SIRUI Co. forecasts a net profit of 165 million CNY to 184 million CNY for 2025, turning from a loss [19] - Shengmei Shanghai expects a revenue increase of 18.91% to 22.47% for 2025, estimating between 6.68 billion CNY and 6.88 billion CNY [20] - Yijun Co. anticipates a net loss of 11 million CNY to 14 million CNY for 2025 [21] - Saint Yuan Environmental Protection expects a net profit increase of 31.79% to 59.24% for 2025, estimating between 240 million CNY and 290 million CNY [22] - Lijun Co. forecasts a net profit decrease of 45.05% to 60.03% for 2025, estimating between 4.8 million CNY and 6.6 million CNY [23] - Xingqi Eye Medicine expects a net profit increase of 95.82% to 121.56% for 2025, estimating between 662 million CNY and 749 million CNY [25] - Beidou Star expects a net loss of 230 million CNY to 290 million CNY for 2025, reducing losses compared to the previous year [26] - Yiling Pharmaceutical anticipates a net profit of 1.2 billion CNY to 1.3 billion CNY for 2025, turning from a loss of 725 million CNY [27] - Zhijiang Bio forecasts a net loss of 32 million CNY to 47 million CNY for 2025, reducing losses compared to the previous year [28] - Yema Battery expects a net profit decrease of 58% to 70% for 2025, estimating between 45.83 million CNY and 64.17 million CNY [29] - Yunmei Energy anticipates a net loss of 410 million CNY to 470 million CNY for 2025 [30] - Yingfang Micro expects a net loss of 69 million CNY to 97 million CNY for 2025 [31] - Guanghua Technology forecasts a net profit of 85 million CNY to 120 million CNY for 2025, turning from a loss [33] Share Buybacks - Hengyi Petrochemical plans to repurchase shares worth 500 million CNY to 1 billion CNY [34] - Yunyi Electric plans to repurchase shares worth 100 million CNY to 150 million CNY [34] - Xidun Pharmaceutical plans to repurchase shares worth 25 million CNY to 50 million CNY [35]

Core Viewpoint - West Point Pharmaceutical has received the drug registration certificate for glucosamine sulfate capsules from the National Medical Products Administration, which enhances the company's product line and market competitiveness [2] Group 1 - The approval of glucosamine sulfate capsules contributes to the diversification of the company's product offerings [2] - This new product is expected to improve the company's competitive position in the market [2]

Group 1 - The company plans to repurchase shares through a centralized bidding method, with a total amount between 25 million and 50 million yuan, and a maximum repurchase price of 42.00 yuan per share, which is 33.59% higher than the current price of 31.44 yuan [1] - The stock price of the company has increased by 10.16% year-to-date [1] - The company specializes in the research, production, and sales of chemical pharmaceutical raw materials and formulations, with main revenue sources being 54.15% from risperidone orally disintegrating tablets and 45.13% from compound ferrous sulfate folic acid tablets [1] Group 2 - As of September 30, the number of shareholders is 7,863, a decrease of 2.91% from the previous period, while the average circulating shares per person increased by 2.97% to 7,426 shares [2] - For the period from January to September 2025, the company reported operating revenue of 189 million yuan, a year-on-year decrease of 1.89%, and a net profit attributable to shareholders of 33.14 million yuan, down 2.70% year-on-year [2] - The company has distributed a total of 63.34 million yuan in dividends since its A-share listing, with 52.83 million yuan distributed over the past three years [3]

北京商报讯（记者 丁宁）1月22日晚间，西点药业（301130）发布公告称，基于对公司未来发展前景的 信心和对公司长期价值的高度认可，为维护全体投资者利益，增强投资者对公司的信心，进一步健全公 司激励机制，充分调动公司员工的积极性，促进公司可持续发展，经综合考虑公司发展战略、经营情 况、财务状况以及未来的盈利能力等因素，公司拟使用自有资金和/或自筹资金通过集中竞价交易方式 回购公司已发行的人民币普通股（A股）股票，回购的股份将在未来适宜时机用于员工持股计划或股权 激励。回购股份的资金总额不低于2500万元（含），不超过5000万元（含）。 ...

格隆汇1月22日丨西点药业(301130.SZ)公布，第八届董事会第十四次会议，审议通过了《关于拟设立全 资子公司的议案》，同意公司拟使用自有资金200万元人民币在吉林省磐石市投资设立全资子公司西点 大药房有限公司（暂定名，最终以市场监督管理部门核准结果为准，简称"西点大药房"），并授权公司 管理层办理西点大药房的设立登记事宜。授权有效期自董事会审议通过之日起至工商变更登记及章程备 案办理完毕之日止。 ...

格隆汇1月22日丨西点药业(301130.SZ)公布，拟回购股份的资金总额不低于人民币2,500万元，不超过人 民币5,000万元，回购股份的价格不超过人民币42.00元/股，用于实施员工持股计划或股权激励。 ...

西点药业（301130）(301130.SZ)公告，公司拟回购公司股份用于实施员工持股计划或股权激励。回购 股份的资金总额不低于2500万元(含)，不超过5000万元(含)。回购股份的价格不超过42.00元/股(含)。回 购股份的实施期限自公司董事会审议通过本次回购股份方案之日起12个月内 ...

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

Core Viewpoint - The company plans to establish a wholly-owned subsidiary, Xidian Pharmacy Co., Ltd., with an investment of 2 million RMB to enhance market expansion and business development [1] Group 1 - The board of directors will hold the 14th meeting of the 8th session on January 22, 2026, to review the proposal for the establishment of the subsidiary [1] - The new subsidiary will primarily engage in drug retail, the operation of Class III medical devices, and the sale of disinfectant equipment [1] - This investment aligns with the company's strategic development plan and aims to facilitate market expansion [1]